ANVS — Annovis Bio, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1477845 ·
Last close
$2.06
Market Cap
$87.64M
52W High
$3.03
52W Low
$1.54
ADV30
1,176,437
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,012,182 | -17,606,382 | 16,243,703 | 14,219,081 | 13,117,645 |
| Dec 2025 | 0 | — | -9,706,149 | -9,834,412 | 21,081,625 | 19,532,338 | 4,230,375 |
| Sep 2025 | 0 | — | -7,434,975 | -7,262,658 | 17,188,961 | 15,286,399 | 4,032,797 |
| Jun 2025 | 0 | — | -6,271,453 | -6,220,058 | 21,454,571 | 17,130,286 | 3,124,124 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,619,703
Investing CF
—
Financing CF
$34,600,125
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-163,703,659
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-29,695,258
Pretax Income TTM
$-28,854,197
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,695,258 | -28,854,197 | 21,081,625 | 4,230,375 | — | -25,619,703 |
| Dec 2024 | 0 | -26,694,928 | -24,590,375 | 13,925,633 | 4,617,987 | — | -21,894,604 |
| Dec 2023 | 0 | -45,035,011 | -56,204,313 | 10,208,264 | 17,959,110 | — | -39,967,304 |
| Dec 2022 | 0 | -25,511,279 | -25,328,567 | 36,022,069 | 7,698,539 | — | -17,312,934 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.16
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.06 · call volume: 894 · put volume: 1
Expected Move to 2027-01-15:
±$1.74
(84.47%) —
implied range
$0.32 –
$3.80
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFVN | Lifevantage Corp | $87.43M | $6.93 | — |
| BHST | BIOHARVEST SCIENCES INC. | $88.63M | $3.91 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $88.72M | $1.29 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $86.45M | $5.77 | — |
| FBIO | Fortress Biotech, Inc. | $89.36M | $2.69 | — |
News headlines (Yahoo Finance, 1h cache)
Annovis Bio Regains NYSE Listing Compliance
2026-05-26 12:00 · Yahoo
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
2026-05-22 00:58 · Yahoo
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
2026-05-20 12:00 · Yahoo
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
2026-05-19 20:06 · Yahoo
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
2026-05-15 11:30 · Yahoo
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
2026-05-07 11:30 · Yahoo
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
2026-04-28 12:00 · Yahoo
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
2026-04-10 12:30 · Yahoo
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
2026-04-09 12:30 · Yahoo
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
2026-04-02 11:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-05-21 20:11:23 | 2026-05-20 | Hoffman Michael B | Dir | P - Purchase | 1.87 | 76344 | 142779 |